1. Search Result
Search Result
Results for "

smarca4-deficient human cancers

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-170824

    PROTACs SWI/SNF Complex Epigenetic Reader Domain Cancer
    SMD-3236 is a SMARCA2 PROTAC degrader with a DC50 of 0.5 nM, a Dmax of 98%, and an IC50 of 42.2 nM against human SMARCA2. SMD-3236 induces proteasome- and ubiquitin-like modification-dependent degradation of SMARCA2 protein by binding to SMARCA2 and VHL-1. SMD-3236 inhibits the growth of SMARCA4-deficient cancer cells. SMD-3236 induces significant and persistent depletion of SMARCA2 in tumor tissues. SMD-3236 suppresses tumor growth in SMARCA4-deficient human cancer xenograft models. SMD-3236 can be used in research related to SMARCA4-deficient cancers such as melanoma, non-small cell lung cancer, and acute myeloid leukemia .
    SMD-3236
  • HY-170817

    Ligands for Target Protein for PROTAC SWI/SNF Complex Cancer
    SMI-1074, a SMARCA bromodomain inhibitor, is a PROTAC target protein ligand (Ligand for Target Protein for PROTAC). SMI-1074 can be used for synthesis SMD-3236 (HY-170824) and SMD-1087 (HY-170828). SMI-1074 can be used for the research of smarca4-deficient cancers .
    SMI-1074
  • HY-181910

    Ligands for Target Protein for PROTAC SWI/SNF Complex Cancer
    SMARCA2 ligand-19 (Compound 26a) is a ligand for the target protein for PROTAC (SMARCA2). SMARCA2 ligand-19 can be used to synthesize PROTACs, such as SMARCA2 degrader-36 (HY-181909) .
    SMARCA2 ligand-19

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: